NCT06130553 - A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors | Biotech Hunter

Enrollment

234

Participants

Timeline

Start Date

January 18, 2024

Primary Completion Date

February 26, 2026

Study Completion Date

February 26, 2026

Conditions

Advanced Solid Tumors That Are MTAP Deficient

Interventions

DRUG

AZD3470

AZD3470 is a novel, potent and selective, second-generation, MTAP-selective, inhibitor of PRMT5.

Trial Locations (20)

3000

RECRUITING

Research Site, Melbourne

8035

RECRUITING

Research Site, Barcelona

15232

RECRUITING

Research Site, Pittsburgh

21231

RECRUITING

Research Site, Baltimore

22031

RECRUITING

Research Site, Fairfax

28027

RECRUITING

Research Site, Madrid

90048

WITHDRAWN

Research Site, West Hollywood

94143

RECRUITING

Research Site, San Francisco

94805

NOT_YET_RECRUITING

Research Site, Villejuif

97239

RECRUITING

Research Site, Portland

100142

RECRUITING

Research Site, Beijing

200433

RECRUITING

Research Site, Shanghai

610041

RECRUITING

Research Site, Chengdu

06510

RECRUITING

Research Site, New Haven

02903

RECRUITING

Research Site, Providence

104-0045

RECRUITING

Research Site, Chūōku

227-8577

RECRUITING

Research Site, Kashiwa

1066CX

RECRUITING

Research Site, Amsterdam

03080

RECRUITING

Research Site, Seoul

06351

RECRUITING

Research Site, Seoul